Yahoo
Frankfurt - Delayed Quote EUR

Novavax, Inc. (NVV1.F)

9.56 +0.96 (+11.16%)
At close: November 6 at 6:49:03 PM GMT+1
Chart Range Bar
Loading chart for NVV1.F
  • Previous Close 8.60
  • Open 8.68
  • Bid --
  • Ask --
  • Day's Range 8.68 - 9.75
  • 52 Week Range 5.41 - 11.84
  • Volume 7,884
  • Avg. Volume 3,351
  • Market Cap (intraday) 1.577B
  • Beta (5Y Monthly) 2.72
  • PE Ratio (TTM) --
  • EPS (TTM) -0.45
  • Earnings Date Nov 5, 2026
  • Forward Dividend & Yield -- (0.00%)
  • 1y Target Est --
  • Moby Rating Bear

Novavax, Inc., a biotechnology company, engages in the discovery, development, and commercialization of vaccines to prevent serious infectious diseases in the United States, Europe, and internationally. The company commercializes Nuvaxovid, a COVID-19 vaccine; and R21 Matrix-M adjuvant malaria vaccine. It has license and collaboration agreements with Sanofi, Pfizer Inc., Takeda Pharmaceutical Company Limited, and Serum Life Sciences Limited for the to develop, manufacture, and commercialize the COVID-19 vaccine. The company was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.

www.novavax.com

749

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Biotechnology

Industry

Recent News

View More

Performance Overview

Trailing total returns as of 11/6/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

NVV1.F
65.28%
S&P 500 (^GSPC)
7.76%

1-Year Return

NVV1.F
45.07%
S&P 500 (^GSPC)
9.77%

3-Year Return

NVV1.F
49.38%
S&P 500 (^GSPC)
68.96%

5-Year Return

NVV1.F
92.84%
S&P 500 (^GSPC)
57.04%

Earnings Trends

View More

Earnings Per Share

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q3 FY26
Revenue 68.3M
Earnings -31.38M
Profit Margin -45.94%

Q4

FY25

Q1

FY26

Q2

FY26

Q3

FY26

-50M
0
50M
100M
-80.0%
-60.0%
-40.0%
-20.0%
0.0%

Statistics

View More

Valuation Measures

Annual
  • Market Cap

  • Enterprise Value

  • Trailing P/E

  • Forward P/E

  • PEG Ratio (current)

  • Price/Sales (ttm)

  • Price/Book (mrq)

  • Enterprise Value/Revenue

  • Enterprise Value/EBITDA

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    -18.64%

  • Return on Assets (ttm)

    -4.22%

  • Return on Equity (ttm)

    --

  • Revenue (ttm)

    411.65M

  • Net Income Avi to Common (ttm)

    -76.73M

  • Diluted EPS (ttm)

    -0.45

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    622.36M

  • Total Debt/Equity (mrq)

    --

  • Levered Free Cash Flow (ttm)

    11.76M

Company Insights

Research Reports

View More

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: